Get help
Specify your contacts and we will contact you to clarify the details.
Intravesical BCG immunotherapy for bladder cancer
Intravesical BCG immunotherapy is the most effective method of intravesical treatment of superficial bladder cancer. It reduces the recurrence rate and prevents the progression of malignant tumors. For bladder cancer, BCG therapy is significantly superior to chemotherapy and reduces the recurrence rate by an average of 40%, while chemotherapy reduces only by 14%.
The BCG vaccine is a suspension of weakened viable Calmette-Guerin bacilli. It was first used in 1921 to vaccinate people against tuberculosis. Further studies have shown that tuberculosis patients are less likely to develop malignant tumors after vaccination. This served as the basis for studying the effectiveness of this treatment method at the bladder level, where Calmette-Guerin bacilli, multiplying intracellularly, stimulate local immunity.
BCG therapy has been used for many years both abroad and in Russia, in particular in the EMC Urological Clinic. Many patients do not notice any side effects after the procedure, but rare cases have been described where BCG therapy could provoke cystitis or prostatitis.
Indications for the use of BCG therapy:
-
Bladder cancer
-
Tumor (including benign) of the bladder
-
Non-invasive (superficial) cancer
Contraindications to the use of BCG therapy:
-
Tuberculosis, including in the anamnesis
-
Hypersensitivity to the components of the drug
-
History of radiation therapy of the bladder
-
Congenital or acquired immunodeficiency (AIDS, leukemia, lymphoma)
-
Conducting immunosuppressive therapy
-
Severe concomitant diseases in the decompensation stage
-
Pregnancy and breastfeeding
Treatment regimen:
The course of treatment and the scheme are prescribed individually by an oncourologist according to the results of a histological examination. Usually, the standard induction course includes 6-8 weekly procedures. Approximately 2 hours after vaccination, the drug is concentrated in the bladder.
-
RESEARCH INSTITUTE OF ONCOLOGY OF THE Russian FEDERATION Ministry of Health of Russia
-
EAU (European Association of Urology)
-
AUA (American Association of Urology)
-
NCCN (National Comprehensive Cancer Network)
-
FICBT (First International Consultation on Bladder Tumours)
Why the EMС
The first and only clinic in Russia, created in the image of the world's leading clinics
Doctors
Grigorev Nikolay
Head of the Urological Clinic, Head of the Department of Urology at the EMC Medical School, Doctor of Medicine, Professor
-
Iskander Abdullin
President of the Association of Young Urologists of Russia (AMUR, Ph.D. of Medical Sciences
-
Ekaterina Korshunova
Ph.D. of Medical Sciences, Doctor of the highest category
-
Vagan Barsegyan
Ph.D. of Medical Sciences
-
Aleksey Kovalenko
-
Gvozdev Mikhail
Doctor of Medicine, Professor, Honored Doctor of the Russian Federation, Doctor of the highest category
-
Tihonova Lyudmila
-
Gvasalia Badri
Professor, Doctor of Medicine
-
Sabirzyanova Zukhra
Ph.D. of Medical Sciences
-
Vsevolod Matveev
President of the Russian Society of Oncourologists, expert of the European Association of Urologists (EAU) section "Prostate Cancer", Doctor of Medicine, Professor
-
Tedeev Rustam
Ph.D. of Medical Sciences
-
Kuznetskiy Yuriy
Doctor of Medicine, Doctor of the highest category, Professor
-
Dariy Evgeniy
Ph.D. of Medical Sciences, Doctor of the highest category
-
Grigorev Nikolay
Head of the Urological Clinic, Head of the Department of Urology at the EMC Medical School, Doctor of Medicine, Professor
- He is a recognized expert in endoscopic urology.
- He has performed more than 5,000 endoscopic and open surgeries on the organs of the genitourinary system
- Member of the Russian Society of Urology, the Russian Society for Endourology and New Technologies, the European Urological Association, the World Endourological Society
Total experience
33 years
Experience in EMC
since 2016
